Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Editas Medicine appointed Dan Ory, M.D., as Chief Medical Officer, effective immediately, strengthening the executive team as the gene editing company advances its lead program toward the clinic. Dr. Ory brings more than 25 years of leadership in cardiovascular and genetic medicine, including CMO roles at Arbor Biotechnologies and Casma Therapeutics and two decades at Washington University School of Medicine researching cholesterol metabolism. He will oversee clinical development strategy and operations as EDIT-401, Editas' lead in vivo development candidate for the potential treatment of hyperlipidemia, moves toward clinical development, while supporting the broader pipeline.
Key figures
- Executive experience years
- more than 25 years
- Peer reviewed publications
- more than 160
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.